A new drug has shown promises in combating Parkinson’s disease by minimizing unwanted side effects.
The pill once a day, the chewing, it was found to relieve symptoms-including stiffness, coordination, vibration and movement-for a longer period of time for patients who were also receiving at least 400 mg of levodopa a day and experiencing “motor fluctuations”, which are periods of use, according to medicines, and symptoms.
So far, Levodopa has been the standard treatment of the first line for Parkinson’s patients.
Levodopa – which has been transformed into dopamine in the brain and aims at D2/D3/D4 dopamine receptors – has been associated with side effects, including sleep disorders, hallucinations, impulse control disorders, weight gain, swelling of the feet and blood pressure changes, according to researchers.
In the study, Tavapadon, which operates by imitating dopamine and aiming at D1/D5 receptors, was found to have the same benefits as levodopa without harmful effects, according to Hubert H. Fernandez, MD, author of the main study and director of the Neurological Restoration at Cleveland Clinic.
“This provides patients with another opportunity to relieve their motor fluctuations usually experienced with levodopa (the best medicine we have so far in Parkinson) in moderate to advanced stages of the disorder,” Fernandez told Fox News Digital.
“This main global, multi-centered judgment showed that patients located on the Tavapadon had significantly more” at the time “and less” time “compared to those who took placebo” and that the drug was well-wiped by patients. “
In the study, researchers measured patient impulse control disorders, excessive daytime drowsiness, blood pressure changes, and changes in weight, and found that the unfavorable effects associated with the tablet were no different than those who received a placebo.
“Of course, this is a short -term study, and we have to wait for our long -term study to be really sure that our preliminary observations remain true,” Fernandez noted. “However, we are very encouraged.”
Researchers presented the results of the Tempo 3 trial at the American Academy of Neurology (AAN) earlier this month in San Diego.
For those who were recently diagnosed and have less severe motor symptoms, Fernandez suggested that a dose once a day and Tavapadon could potentially replace the dosage three times a day of Levodopa.
“If they are looking for levodopa at one point, they will need a lower and less frequency dose, which then reduces their ability to develop motor fluctuations and dyskinesia and other side effects,” he noted in a press release.
For those with the most advanced Parkinson, Tavapadon can be paired with levodopa.
“So no matter what is used, whether at first or as an auxiliary therapy for levodopa, we think this will generally win,” Fernandez added.
Recent research has found that Parkinson’s cases are expected to increase by 2050, affecting up to 25 million people globally.
The highest growth will affect people aged 80 and older, with occasion in that age group predicted to grow up to 196% by 2050, they noted.
While the results of the long -term trial are pending, Abbvie, the manufacturer, will soon submit a request to the Food and Drug Administration for drug approval.
“FDA will then review the app – from there, they can either approve it for use, ask more questions that may not be clear, or require another study or extension to verify some results,” Fernandez said.
“We hope that this new generation of dopamine agonist – being more selective in its stimulation of the dopamine receptor, and given only once a day – will be a significant improvement in the symptomatic treatment of PD symptoms in the early, middle and advanced stages of the disease,” he added.
Dr. Mary Ann Picone, medical director of the MS Center at the Holy Medical Center in Teaneck, New Jersey, was not included in the study, but called the results “very interesting and encouraging as a new tool for improving the quality of life for Parkinson’s disease.”
“One of the main restrictions on long -term use of dopamine is wearing phenomena and the need to dose it more often,” Picone told Fox News Digital.
“Using dopamine agonists helps to extend the long -term benefit of dopamine. Decreased dopamine benefit can lead to” rising ups, “or episodes where patients have increased stiffness and difficulty moving.”
“This new therapy would aim for different receptors and would allow for more time, but without involuntary diskninia (uncontrolled movements) that” can interfere with function. “
#drug #Parkinsoni #shown #effective #clinical #trials #encouraged
Image Source : nypost.com